Abed E.,Jarrar Y.,Alhawari H.,Abdullah S.,Zihlif M. .2020 .How the cytochrome 7a1 (CYP7A1) and ATPbinding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital. International Journal of Clinical Pharmacology and Therapeutics, 59(02) : 99-108.
Adhyaru B. B.,Jacobson T. A. .2018 .Safety and efficacy of statin therapy. Nature Reviews Cardiology, 15(12) : 757-769.
Ahangari N.,Doosti M.,Mobarhan Ghayour,Sahebkar M.,Ferns A.,Pasdar G. A.,A. G. A. .2020 .Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy. Annals of medicine, 52(8) : 462-470.
Akadam-Teker B.,Kurnaz O.,Coskunpinar E.,Daglar-Aday A.,Kucukhuseyin O.,Cakmak H. A.,Teker E.,Bugra Z.,Ozturk O.,Yilmaz-Aydogan H. .2013 .The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease. Gene, 07(2) : 93-98.
Al-Zahrani J.,Shubair M. M.,Al-Ghamdi S.,Alrasheed A. A.,Alduraywish A. A.,Alreshidi F. S.,Alshahrani S. M.,Alsalamah M.,Al-Khateeb B. F.,Ashathri A. I.,ElMetwally A.,Aldossari K. K. .2021 .The prevalence of hypercholesterolemia and associated risk factors in AlKharj population, Saudi Arabia: a cross-sectional survey. BMC cardiovascular disorders, 21(1) : .
Anderson J. M.,Cerda A.,Hirata M. H.,Rodrigues A. C.,Dorea E. L.,Bernik M. M.,Bertolami M. C.,Faludi A. A.,Hirata R. D. .2014 .Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, 02(3) : 256-264.
Basit A.,Sabir S.,Riaz M.,Fawwad A.,Abro M. U. R.,Ahmed K. I.,Ahmed K.,Bilal A.,Butt A.,Devrajani B. R.,Hayder I.,Humayun Y.,Irshad R.,Khan R. A.,Khan A.,Khowaja A. A.,Khowaja R.,Masroor Q.,Mehmood M.,Zafar J. .2016 .NDSP 05: Prevalence and pattern of dyslipidemia in urban and rural areas of Pakistan; a subanalysis from the second National Diabetes Survey of Pakistan (NDSP). Journal of Diabetes & Metabolic Disorders, 19(2) : 1215-1225.
Bi Q.,Zhou X.,Lu Y.,Fu W.,Wang Y.,Wang F.,Wang J. .2022 .Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke. Frontiers in Cardiovascular Medicine, 9 : .
Bougarne N.,Weyers B.,Desmet S. J.,Deckers J.,Ray D. W.,Staels B.,De Bosscher K. .2018 .Molecular actions of PPARΑ in lipid metabolism and inflammation. Endocrine Reviews, 39(5) : 760-802.
Brown W. .1987 .Potential use of fenofibrate and other fibric acid derivatives in the clinic. The American Journal of Medicine, 83(87) : 90876-9343.
Brunham L. R.,Lansberg P. J.,Miao L.,Carter F.,Hovingh C.,Visscher G. K.,Jukema H.,Stalenhoef J. W.,Ross A. F.,Carleton C. J. D.,Kastelein B. C.,Hayden J. J. P.,M. R. J. J. P. .2010 .Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The Pharmacogenomics Journal, 12(3) : 233-237.
Buckley M. M.,Goa K. L.,Price A. H.,Brogden R. N. .1989 .. Probucol. Drugs, 37(6) : 00003495-800.
Carr D. F.,O'Meara H.,Jorgensen A. L.,Campbell J.,Hobbs M.,McCann G.,Pirmohamed T.,M. T. .2013 .SLCO1B1 Genetic variant Associated with Statin-Induced Myopathy: A Proof-of-Concept Study using the Clinical Practice Research Datalink. Clinical Pharmacology & Therapeutics, 94(6) : 695-701.
Chasman D. I. .2004 .Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, 2821(23) : .
Chilbert M. R.,Salah D.,Clark S.,Ma C. M.,Q. C. M. .2022 .Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: Current insights. Drug Design Development and Therapy, 16 : 2177-2186.
Christidis D. S.,Liberopoulos E. N.,Kakafika A. I.,Miltiadous G. A.,Cariolou M.,Ganotakis E. S.,Mikhailidis D. P.,Elisaf M. S. .2006 .The effect of apolipoprotein E polymorphism on the response to LipidLowering treatment with atorvastatin or fenofibrate. Journal of Cardiovascular Pharmacology and Therapeutics, 11(3) : 211-221.
Chung J. Y.,Cho S. K.,Oh E. S.,Lee D. H.,Lim L. A.,Jang S. B.,Lee Y. J.,Park K.,Park M. S. .2011 .Effect of HMGCR variant alleles on Low-Density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. The Journal of Clinical Pharmacology, 52(3) : 339-346.
Colhoun H. M.,Betteridge D. J.,Durrington P. N.,Hitman G. A.,Neil H. A. W.,Livingstone S. J.,Thomason M. J.,Mackness M. I.,Charlton-Menys V.,Fuller J. H. .2004 .Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet, 6736(04) : 16895-5.
Cooper-DeHoff R. M.,Niemi M.,Ramsey L. B.,Luzum J. A.,Tarkiainen E. K.,Straka R. J.,Gong L.,Tuteja S.,Wilke R. A.,Wadelius M.,Larson E. A.,Roden D. M.,Klein T. E.,Yee S. W.,Krauss R. M.,Turner R. M.,Palaniappan L.,Gaedigk A.,Giacomini K. M.,Voora D. .2022 .The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical Pharmacology & Therapeutics, 111(5) : 1007-1021.
Cuevas A.,Fernndez C.,Ferrada L.,Zambrano T.,Rosales A.,Saavedra N.,Salazar L. A. .2015 .HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals. , : .
Pharmacology Clinical . .. , 118(4) : 292-297.
. .. , : .
Dagli-Hernandez C.,Zhou Y.,Lauschke V. M.,Genvigir F. D. V.,Hirata T. D. C.,Hirata M. H.,Hirata R. D. C. .2021 .Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. Pharmacological Reports, 74(1) : 47-66.
Davis H. R.,Veltri E. P. .2007 .ZETIA: inhibition of Niemann-Pick C1-like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. Journal of Atherosclerosis and Thrombosis, 14(3) : 99-108.
DeGorter M. K.,Tirona R. G.,Schwarz U. I.,Choi Y.,Dresser G. K.,Suskin N.,Myers K.,Zou G.,Iwuchukwu O.,Wei W.,Wilke R. A.,Hegele R. A.,Kim R. B. .2013 .Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circulation Cardiovascular Genetics, 6(4) : 400-408.
Stasi Di,MacLeod S. L.,Winters J. D.,BinderMacleod S. A. .2010 .Effects of statins on skeletal muscle: A perspective for physical therapists. Physical Therapy, 90(10) : 1530-1542.
Feng Y.,Li Q.,Ou G.,Yang M.,Du L. .2021 .Bile acid sequestrants: a review of mechanism and design. Journal of Pharmacy and Pharmacology, 73(7) : 855-861.
Frudakis T. N.,Thomas M. J.,Ginjupalli S. N.,Handelin B.,Gabriel R.,Gomez H. J. .2007 .CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenetics and Genomics, 17(9) : 695-707.
Fu Q.,Li Y.,Gao Y.,Yang S.,Lu P.,Jia M.,Zhang L. .2012 .Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. European Journal of Clinical Pharmacology, 69(6) : 1269-1274.
Fukunaga K.,Nakagawa H.,Ishikawa T.,Kubo M.,Mushiroda T. .2016 .ABCB1 polymorphism is associated with atorvastatin-induced liver injury in the Japanese. , : .
. .. , : .
Galicia-Garcia U.,Benito-Vicente A.,Uribe K. B.,Jebari S.,Larrea-Sebal A.,Alonso-Estrada R.,Aguilo-Arce J.,Ostolaza H.,Palacios L.,Martin C. .2020 .Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Scientific Reports, 10(1) : .
Gao J.,Cong H.,Mao Y.,Liu Y.,Zhang Y.,Chen Q.,Liu T.,Cui R. .2013 .[Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome]. PubMed, 05(5) : 9406-558.
Gao Y.,Zhang L.,Fu Q. .2008 .CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. European Journal of Clinical Pharmacology, 64(9) : 877-882.
Giannakopoulou E.,Ragia G.,Kolovou V.,Tavridou A.,Tselepis A. D.,Elisaf M.,Kolovou G.,Manolopoulos V. G. .2014 .No impact of SLCO1B1 521T>C, 388A>G, and 411G>A polymorphisms on response to statin therapy in the Greek population. Molecular Biology Reports, 41(7) : 4631-4638.
Gu G.,Xu X.,Yang Q.,Zeng R. .2014 .Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease. Medical Science Monitor, 20 : 2824-2829.
Guan Z.,Wu K.,Li R.,Yin Y.,Li X.,Zhang S.,Li Y. .2019 .Pharmacogenetics of statins treatment: Efficacy and safety. Journal of Clinical Pharmacy and Therapeutics, 44(6) : 858-867.
Hermann M.,Bogsrud M.,Molden E.,Asberg A.,Mohebi B.,Ose L.,Retterstol K. .2006 .Exposure of atorvastatin is unchanged, but lactone and acid metabolites are increased several-fold in patients with atorvastatininduced myopathy. Clinical Pharmacology & Therapeutics, 02(6) : 532-539.
Hiura Y.,Tabara Y.,Kokubo Y.,Okamura T.,Goto Y.,Nonogi H.,Miki T.,Tomoike H.,Iwai N. .2010 .Association of the functional variant in the 3-Hydroxy-3-. , : .
Journal . .. , 74(3) : 518-522.
Hoenig M. R.,Walker P. J.,Gurnsey C.,Beadle K.,Johnson L. .2011 .The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. Journal of Clinical Lipidology, 01(2) : 91-96.
Hoffmann M. M.,Mrz W.,Genser B.,Drechsler C.,Wanner C. .2011 .Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: The 4D study. Atherosclerosis, 07(2) : 659-662.
Horejs B.,Ceska R. . .(200 0). Apolipoproteins and atherosclerosis: Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiological Research, 49(Suppl 1) : S63-S69.
Iakoubova O. A.,Sabatine M. S.,Rowland C. M.,Tong C. H.,Catanese J. J.,Ranade K.,Simonsen K. L.,Kirchgessner T. G.,Cannon C. P.,Devlin J. J.,Braunwald E. .2007 .Polymorphism in the KIF6 gene and benefit from statins after acute coronary syndromes. Journal of the American College of Cardiology, 10(4) : 449-455.
Ingersgaard M. V.,Andersen T. H.,Norgaard O.,Grabowski D.,Olesen K. .2020 .Reasons for Nonadherence to Statins - A Systematic Review of Reviews Patient Preference and Adherence. , 14 : 675-691.
Jiang J.,Tang Q.,Feng J.,Dai R.,Wang Y.,Yang Y.,Tang X.,Deng C.,Zeng H.,Zhao Y.,Zhang F. .2016 .Association between SLCO1B1 521T>C and 388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. SpringerPlus, 5(1) : .
Jiang X.,Zhang Q.,Chen P.,Li S.,Chen X.,Wang G.,Wang H.,Zhuang M.,Lu M. .2012 .CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. Journal of Clinical Pharmacy and Therapeutics, 01372(6) : 2710-723.
Jose M.,Anandkumar S.,Narmadha M.,Sandeep M. .2012 .A comparative effect of atorvastatin with other statins in patients with hyperlipidemia. Indian Journal of Pharmacology, 44(2) : 0253-7613.
Julius U.,Fischer S. .2012 .Nicotinic acid as a lipidmodifying drug - A review. Atherosclerosis Supplements, 10(1) : 7-13.
Kadam P.,Ashavaid T. F.,Ponde C. K.,Rajani R. M. .2016 .Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. Journal of Clinical Pharmacy and Therapeutics, 41(3) : 329-333.
Kajinami K.,Brousseau M. E.,Nartsupha C.,Ordovas J. M.,Schaefer E. J. .2004 .ATP-binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. Journal of Lipid Research, 45(4) : 653-656.
Kajinami K.,Brousseau M. E.,Ordovas J. M.,Schaefer E. J. .2003 .CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. The American Journal of Cardiology, 08(1) : 104-107.
Kajinami K.,Brousseau M. E.,Ordovas J. M.,Schaefer E. J. .2004 .A promoter polymorphism in cholesterol 7α- hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. , 12(2) : 407-415.
Kajinami K.,Brousseau M. E.,Ordovas J. M.,Schaefer E. J. .2004 .Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. The American Journal of Cardiology, 01(8) : 1046-1050.
Kameyama Y.,Yamashita K.,Kobayashi K.,Hosokawa M.,Chiba K. .2005 .SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics, 0000170913(7) : 513-522.
Karr S. .2017 ."Epidemiology and management of hyperlipidemia.". Am J Manag Care no. 23, (9 Suppl)) : S139-s148.
Keskitalo J. E.,Zolk O.,Fromm M. F.,Kurkinen K. J.,Neuvonen P. J.,Niemi M. .2009 .ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clinical Pharmacology & Therapeutics, 86(2) : 197-203.
Kirac D.,Bayam E.,Dagdelen M.,Gezmis H.,Sarikaya S.,Pala S.,Altunok E. C.,Genc E. .2017 .HMGCR and ApoE mutations may cause different responses to lipidlowering statin therapy. Cellular and Molecular Biology, 63(10) : 43-48.
Kitzmiller J.,Mikulik E.,Dauki A.,Mukherjee C.,Luzum J. .2016 .Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics and Personalized Medicine, 9 : 97-106.
Kivist K. T.,Niemi M.,Schaeffeler E.,Pitkl K.,Tilvis R.,Fromm M. F.,Schwab M.,Eichelbaum M.,Strandberg T. .2004 .Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics, 0000114762(8) : 523-525.
Kolovou G.,Mihas C.,Anagnostopoulou K.,Kolovou V.,Giannakopoulou V.,Kostakou P.,Stamatelatou M.,Mavrogeni S.,Degiannis D.,Mikhailidis D. P. .2010 .Cholesteryl ester transfer protein gene and the effectiveness of lipid-lowering of atorvastatin. The Open Cardiovascular Medicine Journal, 4(1) : 297-301.
Krauss R. M.,Mangravite L. M.,Smith J. D.,Medina M. W.,Wang D.,Guo X.,Rieder M. J.,Simon J. A.,Hulley S. B.,Waters D.,Saad M.,Williams P. T.,Taylor P. T.,Yang H.,Nickerson D. A.,Rotter J. I. .2008 .. , : .
Landray M. J.,Haynes R.,Hopewell J. C.,Parish S.,Aung T.,Tomson J.,Wallendszus K.,Craig M.,Jiang L.,Armitage J. .2014 ."Effects of extended-release niacin with laropiprant in high-risk patients." N Engl J Med no. , (3) : 203-12.
Lee Y. S.,Chun P. .2018 .Effect of SLCO1B1 T521C on statin-induced myotoxicity: a systematic review and metaanalysis. Korean Journal of Clinical Pharmacy, 28(4) : 320-332.
Li J.,Xie L.,Deng N.,Lv B.,Zheng L.,L. L. .2014 .Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease. Genetics and Molecular Research, 24(1) : 2140-2148.
Li Y.,Iakoubova O. A.,Shiffman D.,Devlin J. J.,Forrester J. S.,Superko H. R. .2010 .KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. The American Journal of Cardiology, 05(7) : 994-998.
Li Y.,Sabatine M. S.,Tong C. H.,Ford I.,Kirchgessner T. G.,Packard C. J.,Robertson M.,Rowland C. M.,Bare L. A.,Shepherd J.,Devlin J. J.,Iakoubova O. A. .2010 .Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 129(1) : 17-23.
Lin C.,Chang Y.,Chien S.,Lin Y.,Yeh H. .2018 .Epidemiology of dyslipidemia in the Asia Pacific region. International Journal of Gerontology, 02(1) : 2-6.
Lindgren V.,Luskey K. L.,Russell D. W.,Francke U. .1985 .Human genes involved in cholesterol metabolism:. , : .
Lippi G.,Mattiuzzi C.,Cervellin G. .2019 .Statins' popularity: A global picture. British Journal of Clinical Pharmacology, 85(7) : 1614-1615.
Liu J.,Liu X.,Chen S.,Cai Y.,Yang L.,Lai M.,Ren W.,Zhong B.,S. B. .2017 .SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. European Journal of Clinical Pharmacology, 73(11) : 1409-1416.
Liu Y.,Lv X.,Xie N.,Fang Z.,Ren W.,Gong Y.,Jin Y.,Zhang J. .2012 .Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital. BMC Cardiovascular Disorders, 20(1) : 2018.
Lopez L. M. .2002 .Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors. American Journal of Health-System Pharmacy, 59(12) : 1173-1179.
Miltiadous G.,Xenophontos S.,Bairaktari E.,Ganotakis M.,Cariolou M.,Elisaf M. .2005 .Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenetics and Genomics, 15(4) : 01213011-225.
Misra A.,Khurana L. .2010 .Obesity-related noncommunicable diseases: South Asians vs White Caucasians. International Journal of Obesity, 35(2) : 167-187.
Mohrschladt M. F.,Van Der Sman-De Beer F.,Hofman M. K.,Van Der Krabben M.,Westendorp R. G.,Smelt A. H. .2005 .TaqIB polymorphism in the CETP gene: the influence on incidence of cardiovascular disease in statintreated patients with familial hypercholesterolemia. , : .
Morofuji Y.,Nakagawa S.,Ujifuku K.,Fujimoto T.,Otsuka K.,Niwa M.,Tsutsumi K. .2022 .Beyond LipidLowering: Effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals, 15(2) : .
Munshi A. .2012 .Genetic variation in MDR1, LPL, and eNOS genes and the response to atorvastatin treatment in ischemic stroke. Human Genetics, 131(11) : 1775-1781.
Noriega V.,Pennanen C.,Snchez M. P.,Chiong M.,Llancaqueo M.,Lavandero S.,Prieto J. C.,-MethylglutarylCoenzyme A .2008 .Response to Atorvastatin in Coronary Artery Disease Patients. Basic & Clinical Pharmacology & Toxicology, 00341(3) : 7843-215.
Nozawa T.,Nakajima M.,Tamai I.,Noda K.,Nezu J.,Sai Y.,Tsuji A.,Yokoi T. .2002 .Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. Journal of Pharmacology and Experimental Therapeutics, 302(2) : 804-813.
Onwe P.,Folawiyo M.,Anyigor-Ogah C. S.,Umahi G.,Okorocha A. E.,Afoke A. .2015 .Hyperlipidemia: Etiology and possible control. IOSR Journal of Dental and Medical Sciences, 14(10) : 0853-100.
Padhye M.,Yadav N. .2022 .Plethora of adverse drug reactions in the geriatric population receiving statin therapy for dyslipidaemia. Journal of Family Medicine and Primary Care, 2205(7) : 3726-3729.
Pedro-Botet J.,Schaefer E. J.,Bakker-Arkema R. G.,Black D. M.,Stein E. M.,Corella D.,Ordovas J. M. .2001 .Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis, 9150(01) : 00410-5.
Peng C.,Ding Y.,Yi X.,Shen Y.,Dong Z.,Cao L.,Li Q.,Ren H.,He L.,Zhou D.,Chen X. .2018 .. , : .
. .Polymorphisms in CYP450 genes and the therapeutic. , : .
.2018 .. , 02 : .
Poduri A.,Khullar M.,Bahl A.,Sehrawat B.,Sharma Y.,Talwar K. K. .2009 .Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, andCYP7A1Genes as predictors of Lipid-Lowering response to atorvastatin therapy. DNA And Cell Biology, 29(10) : 629-637.
Postmus I.,Trompet S.,Deshmukh H. A.,Barnes M. R.,Li X.,Warren H. R.,Chasman D. I.,Zhou K.,Arsenault B. J.,Donnelly L. A.,Wiggins K. L.,Avery C. L.,Griffin P.,Feng Q.,Taylor Q.,Li G.,Evans D. S.,Smith A. V.,De Keyser C. E.,Spencer C. C. A. .2014 .Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 5(1) : .
Prado Y.,Arencibia A.,Zambrano T.,Salazar L. A. .2017 .Gender-Specific Association Between ABCC2-24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin. Basic & Clinical Pharmacology & Toxicology, 122(5) : 517-522.
Qu K.,Zhang C.,Dong L.,Wang S.,Zhang Z.,Zhang L. .2019 .Association of ABCB1 polymorphisms with lipid homeostasis and liver injury response to atorvastatin in the Chinese population. Canadian Journal of Physiology and Pharmacology, 98(1) : 15-22.
Ragia G.,Kolovou V.,Tavridou A.,Elens L.,Tselepis A. D.,Elisaf M.,Van Schaik,Kolovou R. H.,Manolopoulos G.,V. G. G. .2014 .No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabolism and Personalized Therapy, 30(1) : 43-48.
Ramakumari N.,Indumathi B.,Katkam S. K.,Kutala V. K. .2018 .Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart Journal, 07 : S120-S125.
Rebecchi I. M. M.,Rodrigues A. C.,Arazi S. S.,Genvigir F. D. V.,Willrich M. a. V.,Hirata M. H.,Soares S. A.,Bertolami M. C.,Faludi A. A.,Bernik M. M. S.,Dorea E. L.,Dagli M. L. Z.,Avanzo J. L.,Hirata R. D. C. .2008 .ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochemical Pharmacology, 09(1) : 66-75.
Rizwan M.,Aslam N.,Ashfaq U. A.,Hayat M.,Hussain S. M. .2021 .SNP of HMGCR and Apo E genes and their impact in response to statin therapy in hypercholesterolemic and hypertriglyceridemic patients in Pakistan. Pakistan journal of pharmaceutical sciences, 34(4) : 1577-1583.
Rodrigues A. C.,Perin P. M. S.,Purim S. G.,Silbiger V. N.,Genvigir F. D. V.,Willrich M. a. V.,Arazi S. S.,Luchessi A. D.,Hirata M. H.,Bernik M. M. S.,Dorea E. L.,Santos C.,Faludi A. A.,Bertolami M. C.,Salas A.,Freire A.,Lareu M. V.,Phillips C.,Porras-Hurtado L.,Hirata R. D. C. .2011 .Pharmacogenetics of OATP Transporters reveals that SLCO1B1 C.388A G variant is determinant of increased atorvastatin response. International Journal of Molecular Sciences, 12(9) : 5815-5827.
Rodrigues A.,Rebecchi I.,Bertolami M.,Faludi A.,Hirata M.,Hirata R. .2005 .High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Brazilian Journal of Medical and Biological Research, 38(9) : 1389-1397.
Rosales A.,Alvear M.,Cuevas A.,Saavedra N.,Zambrano T.,Salazar L. A. .2011 .Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clinica Chimica Acta, 11(3-4) : 495-501.
Saha S. P.,Banks M. A.,Whayne T. F. .2020 .Managing Cardiovascular Risk Factors without Medications: What is the Evidence? Cardiovascular & Hematological Agents in. , : .
Chemistry Medicinal . .. , 19(1) : 8-16.
. .. , : .
Sałacka A.,Biczak -Kuleta A.,Kaczmarczyk M.,Hornowska I.,Safranow K.,Clark J. S. C. .2014 .Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment - a pilot study. Biomolecules and Biomedicine, 3(3) : 144-149.
Sałacka A.,Boro A.,Gorcy I.,Hornowska I.,Safranow K.,Ciechanowicz A. .2021 .An association of ABCG8: rs11887534 polymorphism and HDL-cholesterol response to statin treatment in the Polish population. Pharmacological Reports, 73(6) : 1781-1786.
Salami J. A.,Warraich H.,Valero-Elizondo J.,Spatz E. S.,Desai N. R.,Rana J.S.,Virani S. S.,Blankstein R.,Khera A.,Blaha M. J.,Blumenthal R. S.,Lloyd-Jones D.,Nasir K. .2016 .National trends in statin use and expenditures in the US adult population from 2002 to 2013. , 2(1) : .
Schaiff R. A.,Moe R. M.,Krichbaum D. W. .2008 .An overview of cholesterol management. American Health & Drug Benefits, 1(9) : 39-48.
Simon J. A.,Lin F.,Hulley S. B.,Blanche P. J.,Waters D.,Shiboski S.,Rotter J. I.,Nickerson D. A.,Yang H.,Saad M.,Krauss R. M. .2005 .Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study. The American Journal of Cardiology, 09(6) : 843-850.
Skvrce N. M.,arini N. M.,imi N. M.,Ganoci L.,Katanec D. M.,Boina N. .2015 .ABCG2 Gene Polymorphisms as risk factors for atorvastatin Adverse reactions: A CaseControl Study. , 16(8) : 803-815.
Srivastava A.,Garg N.,Srivastava A.,Srivastava K.,Mittal B. .2010 .Effect of genetic variant (rs11887534) in the ABCG8 gene in coronary artery disease and response to atorvastatin therapy. DOAJ (DOAJ: Directory of Open Access Journals), 28(5) : 307-313.
Stroes E. S.,Thompson P. D.,Corsini A.,Vladutiu G. D.,Raal F. J.,Ray K. K.,Roden M.,Stein E.,Tokgzolu L.,Nordestgaard B. G.,Bruckert E.,De Backer G.,Krauss R. M.,Laufs U.,Santos R. D.,Hegele R. A.,Hovingh G. K.,Leiter L. A.,Mach F.,Wiklund O. .2015 .Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36(17) : 1012-1022.
Tarling E. J.,De Aguiar Vallim T. Q.,Edwards P. A. .2013 .Role of ABC transporters in lipid transport and human disease. Trends in Endocrinology and Metabolism, 01(7) : 342-350.
Thompson J. F.,Hyde C. L.,Wood L. S.,Paciga S. A.,Hinds D. A.,Cox D. R.,Hovingh G. K.,Kastelein J. J. .2009 .Comprehensive Whole-Genome and Candidate gene analysis for response to statin therapy in the treating New Targets (TNT) cohort. Circulation Cardiovascular Genetics, 2(2) : 173-181.
Torres M. T. M.,Mora-Hernndez S.,Crdenas N. a. V.,Jaimes A. G. .2014 .A mutation in the LDLR gene and clinical heterogeneity. Journal of Clinical Lipidology, 05(5) : 525-527.
Trompet S.,Postmus I.,Warren H. R.,Noordam R.,Smit R. A. J.,Theusch E.,Li X.,Arsenault B.,Chasman D. I.,Hitman G. A.,Munroe P. B.,Rotter J. I.,Psaty B. M.,Caulfield M. J.,Krauss R. M.,Cupples A. L.,Jukema W. J. .2021 .The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction. , 12 : .
Turner R. M.,Fontana V.,Zhang J. E.,Carr D.,Yin P.,Morris A. P.,Pirmohamed M. .2020 .A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clinical Pharmacology & Therapeutics, 108(2) : 287-297.
Van Venrooij F. V.,Stolk R. P.,Banga J.,Sijmonsma T. P.,Van Tol A.,Erkelens D. W.,Dallinga-Thie G. M. .2003 .Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care, 26(4) : 1216-1223.
Vrablk M.,Hubek J. A.,Dlouh D.,Lnsk V.,Rynekrov J.,Zlatohlvek L.,Pruskov M.,Admkov V. .2012 .Impact of variants within seven candidate genes on statin treatment efficacy. Physiological Research, : 609-617.
Wang T.,Wu J.,Xu T.,Feng L.,Shen J.,Sun H.,Li L.,Yu H.,L. H.,Disorders - Drug Targets H. .2023 .The ABCB1 C3435T polymorphism is associated with triglyceride reduction in atorvastatin-treated Uyghur patients with coronary heart disease and dyslipidemia: An observational study. Endocrine, 23(9) : 1215-1228.
Wang Y.,Du X.,Zhao R.,Niu J.,Wang H.,Li J. .2021 .Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases. Annals of the Academy of Medicine Singapore, 50(6) : 474-480.
Wei K.,Zhang L. .2015 .Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid-Lowering Response with Atorvastatin. Clinical Drug Investigation, 35(9) : 583-591.
Wei K.,Zhang L.,Zhang Y.,Hu X. .2010 .Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. Journal of Clinical Pharmacy and Therapeutics, 01227(6) : 2710-733.
Wilke R. A.,Moore J. H.,Burmester J. K. .2005 .Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenetics and Genomics, 15(6) : 01213011-421.
Woo H. I.,Kim S. R.,Huh W.,Ko J.,Lee S. .2017 .Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Design Development and Therapy, 11 : 1135-1146.
Yao Y. S.,Li Di,Zeng T.,Z. H. T. .2020 .Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids in Health and Disease, 19(1) : .
Yue Y.,Bai X.,Li H.,Hu Y.,Liu L.,Mao L.,Yang J.,Dila X.,N. X. .2016 .Gene polymorphisms affect the effectiveness of atorvastatin in treating ischemic stroke patients. Cellular Physiology and Biochemistry, 39(2) : 630-638.
Zambrano T.,Hirata M. H.,Dorea E. L.,Pinto G. A.,Gusukuma M. C.,Bertolami M. C.,Salazar L. A.,Hirata R. D. .2015 .Impact of 3UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: A pilot study. International Journal of Clinical and Experimental Medicine, 8(4) : 5978-5988.
Zhang L.,He S.,Li Z.,Gan X.,Li S.,Yang X.,Zheng N.,F. N. .2019 .Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia. Lipids in Health and Disease, 18(1) : .
Zhang L.,Lv H.,Wang Q.,Kang D.,X. D.,Li G.,X. G. .2019 .Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke. Current Pharmaceutical Design, 25(14) : 1663-1670.
Zhang N.,Gao J.,Sun Y.,G. Y. .2017 .[Influence of PCSK9 gene E670G polymorphism on the risk of atherosclerotic coronary heart disease and plasma lipid level]. PubMed, 05(5) : 9406-754.
Zihlif M.,Otoum S.,Shhab M. A.,Almadani Z.,Momani M.,Alhawari H.,Jibrini N. E.,Jarrar Y.,Al-Ameer H.,Imraish A. .2022 .No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients. Drug Metabolism and Personalized Therapy, 37(4) : 369-374.
. .. , 335 : .
. .. , : .
. .. , : .
(Chasman .2004 .. , : .
(Rosales .2012 .. , : .
(Gao .2008 .. Fu, : .
(Ragia .2015 .. , : .
(Willrich .2005 .(Kajinami. , : .
Poduri .2016 .. , : .